Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

Philadelphia Eagles offensive coordinator Kellen Moore is sticking around in New Orleans. Moore, as expected, has agreed to terms to become the next head coach of the Saints.

The Philadelphia Eagles to have Super Bowl LIX parade on February 14th. "GMFB" debates what does Super Bowl LIX loss do for ...

增资完成后，曲水奥城的股权结构中，王中锋持有31.5%的股权，杨瑞娜持有6.35%的股权，而西藏惠儒则持有62.15%的股权。增资前，王中锋和杨瑞娜夫妇通过曲水奥城持有濮阳惠成1.03亿股股份，占总股本的34.78%。增资后，西藏惠儒将间接控制濮阳惠成34.78%的股份，合计控制股份的比例为35.27%，剔除回购专户股份后，实际控制权比例为35.74%。此次股权结构调整并未导致控股股东和实际控制人 ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

新京报讯 2月11日，百奥泰发布公告，公司与Intas Pharmaceuticals Ltd.（以下简称“Intas”）签署授权许可与商业化协议，将公司的BAT2506（戈利木单抗）注射液在美国市场的独占的产品商业化权益有偿许可给Intas（以下简称“协议”或“本协议”）。百奥泰将负责研发、生产及商业化供应，Intas将通过其美国子公司Accord BioPharma ...

百奥泰将负责研发、生产及商业化供应，Intas 将通过其美国子公司 AccordBioPharmaInc.负责 BAT2506 在美国的商业化活动。 首付款及里程碑款总金额最高至 1.645 亿美元，其中包括 2100万美元首付款、累计不超过 1.435 亿美元里程碑付款，以及净销售额的两位数百分比作为收入分成。

2024年10月，广西中医药大学附属瑞康医院(广西壮族自治区中西医结合医院)在Journal of ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

《科创板日报》2月10日讯（记者 邱思雨） 百奥泰披露又一笔“出海”交易。 今日（2月10日）晚间，百奥泰公告，公司与Intas Pharmaceuticals ...

The coolest piece of outerwear we tested all season is actually pretty terrible for skiing, so we came up with some better ...

A study from Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn’s disease. In this latest study, HLA DQA1*05 positive children just ...